Alzheimer's Disease Research - Completed Award

	Bruce Lamb, Ph.D. The Cleveland Clinic Foundation Cleveland, OH Title: Microglia , CX3CR1and Alzheimer's Disease Pathogenesis Non-Technical Title: Activation of the immune system in AD Duration: April 1, 2007 - March 31, 2011 Award Type: Standard Award Amount: $400,000
Summary: The focus of the current proposal is to determine the role of CX3CR1 plays in activation of the immune system, neuronal cell death and Aß deposition in two different mouse models of AD as well as to gain insight into the mechanisms involved. The long-term goal of this project is to gain insight into the role inflammation play in AD and thus provide potential new avenues of therapeutic intervention.

Details:

Alzheimer's disease (AD), the most common dementing disorder of late life, is now the fourth major cause of death in the developed world. A definitive diagnosis of AD requires examination of brain tissue for the presence of distinctive AD pathological alterations including filamentous inclusions (termed neurofibrillary tangles) and extracellular deposits of the ß-amyloid peptide (Aß, termed senile plaques). In addition, while there is considerable data that suggests there is a marked activation of the immune system within the AD brain, there is little evidence that altered inflammation plays a direct role in the observed neurodegeneration. It was recently demonstrated that alterations in inflammation within the brain, through genetically engineered mutations in the chemokine receptor, CX3CR1, can directly result in increased neuronal cell loss in three different mouse models of neurodegeneration. The focus of the current proposal is to determine the role of CX3CR1 plays in activation of the immune system, neuronal cell death and Aß deposition in two different mouse models of AD as well as to gain insight into the mechanisms involved. The long-term goal of this project is to gain insight into the role inflammation play in AD and thus provide potential new avenues of therapeutic intervention.

Publications:

Varvel, N.H., Bhaskar, K., Herrup, K., and B.T. Lamb. (2008) The role of inflammation and beta-amyloid oligomers in triggering aberrant neuronal cell cycle events. Alzheimer's Disease Keystone Symposia, Keystone, CO, 2008 Oct 22;28(43):10786-93.

Lee, S., Varvel, N.H., Konerth, M.E., Xu, G., Cardona, A.E., Ransohoff, R.M., and B.T. Lamb. CX3CR1 deficiency alters microglial activation and reduces beta-amyloid deposition in two Alzheimer's disease mouse models. Am. J. Pathol., 177:2549-2562, 2010 (Cover article).

Bhaskar, K., Konerth, M.E., Kokiko-Cochran, O.N., Cardona, A.E., Ransohoff, R.M., and B.T. Lamb. Regulation of tau pathology by the microglial fractakine receptor. Neuron, 68:19-31, 2010.

Progress Updates:

Dr. Bruce Lamb and colleagues examined the roles played by a protein, called CX3CR1, in two mouse models of Alzheimer’s disease. Specifically, the researchers looked at whether CX3CR1: 1) activates microglia (a type of immune cell); 2) interferes with nerve cell function or promotes death; and/or 3) plays a part in beta-amyloid protein deposits or disease-associated changes to tau protein.  These researchers discovered that CX3CR1 deficiency leads to reduced beta-amyloid deposits and an activation of microglia.  It was determined that removing CX3CR1from microglia increased the removal of Aß.  In addition, these researchers observed that CX3CR1 deficiency leads to disease-associated changes to tau protein.  Taken together, these results suggest that CX3CR1 may be a potential therapeutic target for Alzheimer’s disease.